Target intelligence / Profile preview

Off-target genomic DNA adenine bases at partially matched sgRNA sites (DNA off-target sites)

Target
DNA off-target sites
Molecular classification
Genomic DNA, Nucleic acid, Other
01

Overview

Off-target genomic DNA adenine bases at partially matched sgRNA sites refer to unintended genomic loci where adenine base editors (ABEs) induce mutations (Gaudelli et al., 2017, Nature). These events occur when the single guide RNA (sgRNA) directs the CRISPR-Cas complex to DNA sequences that share high homology with the intended target, allowing for mismatch tolerance (Rees & Liu, 2018, Nature Reviews Genetics). At these sites, the deoxyadenosine deaminase component of the ABE converts adenine to inosine, which is subsequently replicated or repaired as guanine, resulting in permanent A-to-G transitions (Kim et al., 2019, Nature Biotechnology). Such off-target activity is a primary safety concern in genome editing because it can lead to genotoxicity, the activation of oncogenes, or the disruption of tumor suppressor genes (Zuo et al., 2019, Science). Consequently, identifying and minimizing these off-target effects is essential for the clinical development of base editing therapies. Advanced sequencing methods like CIRCLE-seq and GOTI are employed to detect these unintended modifications across the genome to ensure therapeutic precision (Zuo et al., 2019, Science).

Other names
Off-target adenine deaminationsgRNA-dependent DNA off-targetsUnintended A-to-G transitionsCRISPR-Cas9 off-target sites
02

Mechanism of action

Adenine base editors (ABEs) utilize a guide RNA to target a Cas9 nickase fused to a deoxyadenosine deaminase (e.g., TadA) to a specific DNA sequence. At partially matched off-target sites, the deaminase converts adenine to inosine, which is read as guanine during DNA replication, resulting in an A-to-G transition (Gaudelli et al., 2017, Nature).

03

Biological functions

Genomic integrityDNA sequence conservationOther
04

Disease associations

CancerGenetic disordersGenotoxicityOther
05

Safety considerations

GenotoxicityOncogene activationTumor suppressor inactivationUnintended phenotypic changesChromosomal instability
06

Interacting drugs

Adenine Base Editors (ABEs)

1 more in the full profile.

07

Biomarkers

CIRCLE-seqGUIDE-seqDigenome-seqGOTI (Genome-wide Off-target analysis by Two-cell embryo Injection)Whole-genome sequencing (WGS)

Beyond the preview

Go deeper on Off-target genomic DNA adenine bases at partially matched sgRNA sites (DNA off-target sites).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target genomic DNA adenine bases at partially matched sgRNA sites (DNA off-target sites).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call